ctl-002
mAbexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Dec 9, 2020 (NCT04725474)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095326 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07219459 | Phase 2 | Feb 28, 2026 | CatalYm GmbH |
| NCT07112196 | Phase 2/Phase 3 (Phase 3) | Feb 28, 2026 | CatalYm GmbH |
| NCT07246863 | Phase 2 | Oct 7, 2025 | CatalYm GmbH |
| NCT07098988 | Phase 2 | Aug 1, 2025 | CatalYm GmbH |
| NCT06059547 | Phase 2 | Sep 6, 2023 | CatalYm GmbH |
| NCT04725474 | Phase 1 | Dec 9, 2020 | CatalYm GmbH, CatylYm GmbH |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CatalYm GmbH | For profit | 6 | 6 | 3 | 2020 |
| CatylYm GmbH | For profit | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1